Loading…

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Saved in:

Bibliographic Details
Published in:	Blood 2022-11, Vol.140 (Supplement 1), p.1856-1858
Main Authors:	Ferreri, Christopher J., Hildebrandt, Michelle A.T., Hashmi, Hamza, Shune, Leyla O., McGuirk, Joseph P., Sborov, Douglas W., Wagner, Charlotte B, Kocoglu, M. Hakan, Atrash, Shebli, Voorhees, Peter M., Khouri, Jack, Dima, Danai, Afrough, Aimaz, Sannareddy, Aishwarya, Simmons, Gary, Davis, James, Kalariya, Nilesh, Peres, Lauren C., Alsina, Melissa, Locke, Frederick L., Sidana, Surbhi, Hansen, Doris K., Patel, Krina, Castaneda Puglianini, Omar Alexis
Format:	Article
Language:	English
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!